The Zacks Analyst Blog Highlights: Sangamo BioSciences, Biogen Idec, Shire, Actelion and eHealth

Jan 14, 2014, 09:30 ET from Zacks Investment Research, Inc.

CHICAGO, Jan. 14, 2014 /PRNewswire/ -- announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Sangamo BioSciences, Inc. (Nasdaq: SGMO-Free Report), Biogen Idec (Nasdaq: BIIB-Free Report), Shire (Nasdaq: SHPG-Free Report), Actelion (OTC:ALIOF-Free Report) and eHealth, Inc. (Nasdaq: EHTH-Free Report).


Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Monday's Analyst Blog:

Sangamo and Biogen Tie Up

A lot of pharmaceutical companies enter into collaboration and license agreements to obtain funding for research and development programs, to leverage technological knowhow as well as gain access to marketing expertise.

Sangamo BioSciences, Inc. (Nasdaq: SGMO-Free Report) recently entered into a worldwide collaboration and license agreement with Biogen Idec (Nasdaq: BIIB-Free Report).

The deal primarily focuses on the development of therapeutics for hemoglobinopathies which results from the abnormal structure or underproduction of hemoglobin.

The agreement will enable Biogen to leverage Sangamo's proprietary genome-editing technology platform to develop treatments targeting sickle cell disease and beta-thalassemia.

As per the agreement, Sangamo will be responsible for all research and development work through the first clinical trial in beta-thalassemia / the sickle-cell disease program. Both the companies will work together to submit an Investigational New Drug (IND) application for sickle-cell disease.

In addition, Sangamo retains an option to co-promote any licensed product to treat sickle-cell disease and beta-thalassemia in the U.S. while Biogen will be responsible for the clinical development and commercialization of products arising from the alliance on a worldwide basis.

Sangamo will earn a $20 million upfront payment. Biogen will fund all the internal and external research and development program related costs. Moreover, Sangamo will receive additional milestone payments of approximately $300 million.

Meanwhile, Sangamo expects to file an IND for hemophilia A and B with its collaboration partner Shire (Nasdaq: SHPG-Free Report) and for beta-thalassemia with Biogen in 2014. The company also plans to submit an IND for its HIV candidate in  in 2014. Further, Sangamo intends to file an IND for Hunginton's disease with Shire in 2015.

The collaboration agreements with Biogen and Shire bodes well for Sangamo and we look forward to updates on IND applications in 2014.

Sangamo currently carries a Zacks Rank #2 (Buy). Investors may also consider Actelion (OTC:ALIOF-Free Report) at current levels, carrying Zacks Rank #1 (Strong Buy).

Sneak Preview of eHealth's Q4 Results

Shares of eHealth, Inc. (Nasdaq: EHTH-Free Report) has been on an uptrend since the private health insurance exchange announced its preliminary results for the fourth quarter and full year 2013 on Jan 8. Its share price has gained nearly 24% since then.

eHealth noted that demand for its Individual & Family Plan (IFP) product increased substantially in the fourth quarter. As such, it estimated that submitted applications for its IFP product surged almost 50% in the fourth quarter. The company also predicted fourth-quarter submitted applications for total Medicare products increased more than 65% while submitted applications for Medicare Advantage product increased more than 35% over the year-ago period.

These are expected to drive fourth-quarter revenues to a range of $53 to $55 million, and in turn, boost full-year revenues to a range of $178 million to $180 million. The top line for 2013 is likely to figure above the company guidance of $168 million to $174 million.

For full year 2013, earnings are estimated to be between 34–41 cents per share, well above the Zacks Consensus Estimate of 24 cents. The bottom line may, however, fail to meet the company's guidance of 61–71 cents per share.

Earnings before interest, depreciation and amortization (EBITDA) for full year 2013 is estimated in the range of $16.0–$18.0 million, below the company's guidance of $23–$29 million.

eHealth estimates fourth-quarter bottom line to range between loss of 3 cents and earnings of 4 cents, shy of the Zacks Consensus Estimate of earnings of 6 cents. EBITDA for the fourth quarter is estimated to be in the range of $1$3 million.

With respect to earnings performance, eHealth delivered a positive earnings surprise in one of the last three reported quarters while managing to meet the Zacks Consensus Estimate in the other two. However our proven model does not conclusively show that eHealth is likely to beat earnings this quarter. This is because a Zacks Rank #3 (Hold) combined with an Earnings ESP of -83.3% makes prediction difficult.  

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on SGMO - FREE

Get the full Report on BIIB - FREE

Get the full Report on SHPG - FREE

Get the full Report on ALIOF - FREE

Get the full Report on EHTH - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

SOURCE Zacks Investment Research, Inc.